Daiichi Sankyo, Ranbaxy Launch Evista In Romania

Daiichi Sankyo and Ranbaxy have announced that Terapia, a subsidiary of Ranbaxy in Romania, will market the osteoporosis medication, Evista in Romania.

Takashi Shoda, president and CEO of Daiichi Sankyo, said: “We are delighted to announce this latest of the many synergies we will realize through our cooperation with Ranbaxy. We continue to explore other collaborations with Ranbaxy that will help optimize our growth.”

Atul Sobti, managing director and CEO of Ranbaxy, said: “The launch of Evista by Terapia Ranbaxy in Romania marks our first international endeavour as a global partnership. Terapia Ranbaxy is a strong player in Europe, and we will provide a unique platform to Daiichi Sankyo for the launch of Evista, and many more new products in the future.”

Earlier in 2006, Daiichi Sankyo acquired the marketing and distribution rights for Evista, an osteoporosis treatment, in six European countries from Eli Lilly and Company. In 2008, Daiichi Sankyo acquired additional rights for the drug covering all remaining countries in Europe, with the exception of Greece.